HOSPITAL CLINICO UNIVERSITARIO
Avda. Ramón y Cajal, 3
Tfno. 983 42 00 00
47005 - VALLADOLID

Budesonide suspension for Eosinophilic Esophagitis

S. Fernández Peña[1], S. Fernández Cañabate[1], L. García López[1] ,V. Cabezas Martín[1],Cardaba Pérez C[1], M. Izquierdo Navarro[1], C. Matallana Martín[1], T. Sánchez Sánchez[1].

[1]Hospital Clínico Universitario, Pharmacy, Valladolid, Spain.



Introduction:

Eosinophilic esophagitis (EoE) is a clinicopathologic disease characterized by esophageal eosinophilia and gastrointestinal symptoms. It is caused by immunologic reactions to ingested and inhaled allergens.The diagnosis is established if at least 15 eosinophils per high-powered field are detected in mucosal biopsies.

Objective:

Describe and evaluate the efficacy of oral viscous Budesonide for EoE in pediatric patient.



Methods:

Preparation of viscous oral Budesonide concentration 0.25mg/ml **:** pour the contents of 60 vials of budesonide 0.50mg/ml inhalation suspension (2ml) in a glass beaker. Weigh Sodium Benzoate and Sodium Saccharin and add. Add the glycerin with constant stirring until blended. Add the strawberry essence and water to complete a volume of 234ml. Incorporate Xanthan Gum on top without mixing and add water to 240ml.

Result:

The patient presented a improvement in the EoE during the treatment.



Discussion:

The patient presented eosinophilic enteritis and esophagitis, despite having been treated with IBP, antihistaminic, and dietary therapy. He was receiving budesonide 500mcg/12h and dietary therapy for two months. He showed a significant improvement. Endoscopy was completely normalized. Unfortunately, 3 months later with the cessation of the oral steroids, the patient reported recurrence of symptoms.

Conclusions:

Oral Budesonide improved esophageal eosinophilic and symptoms in patients with EoE, and induced full remission in our patient.
Unfortunately, the therapeutic effect is abolished following cessation of treatment. Therefore, patients may have to continue on a therapeutic dosage for an indefinite amount of time.

No conflict of interest

DI-097